Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARγ agonist in LPS-exposed guinea pigs

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2009, Pages 183-189

  Sharma, Rohini ^a   Kaundal, Ravinder K ^a   Sharma, Shyam Sunder ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

COPD; Inflammation; Inhalation exposure; LPS; Neutrophilia; Oxidative stress; Pioglitazone; PPAR ; Pulmonary dysfunction

Indexed keywords

LIPOPOLYSACCHARIDE; MALONALDEHYDE; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING RATE; BRONCHOSPASM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GUINEA PIG; HISTOPATHOLOGY; LEUKOCYTE COUNT; LUNG FUNCTION; LUNG LAVAGE; MALE; NEUTROPHILIA; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; TIDAL VOLUME;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; ESCHERICHIA COLI PROTEINS; GUINEA PIGS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; LUNG; LUNG DISEASES; MALE; MALONDIALDEHYDE; NEUTROPHILS; OXIDATIVE STRESS; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; PLETHYSMOGRAPHY, WHOLE BODY; PNEUMONIA; PPAR GAMMA; ROLIPRAM; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349266761     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.11.011     Document Type: Article

References (36)

1. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 258-266
2. Magnussen H. COPD: an inflammatory disease of the airways?. Pneumologie 58 (2004) 320-324
3. Molfino N.A., and Jeffery P.K. Chronic Obstructive Pulmonary Disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 20 (2007) 462-472
4. Kharitonov S.A., and Sjobring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 14 (2007) 83-100
5. Jackson A.D. Airway goblet-cell mucus secretion. Trends Pharmacol Sci 22 (2001) 39-45
6. Toward T.J., and Broadley K.J. Goblet cell hyperplasia, airway function, and leukocyte infiltration after chronic lipopolysaccharide exposure in conscious Guinea pigs: effects of rolipram and dexamethasone. J Pharmacol Exp Ther 302 (2002) 814-821
7. Rogers D.F. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 18 (2005) 1-8
8. Cai S., Chen P., and Zhu Y. Airway inflammation and macrophage inflammatory protein-1alpha, gelatinase B level in patients with COPD. Zhonghua Jie He He Hu Xi Za Zhi 24 (2001) 429-432
9. de Godoy I., Donahoe M., Calhoun W.J., Mancino J., and Rogers R.M. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153 (1996) 633-637
10. Hoshino T., Kato S., Oka N., Imaoka H., Kinoshita T., Takei S., et al. Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176 (2007) 49-62
11. Kota B.P., Huang T.H., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 51 (2005) 85-94
12. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110 (2006) 371-385
13. Széles L., Töröcsik D., and Nagy L. PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 8 (2007) 1014-1030
14. Belvisi M.G., Hele D.J., and Birrell M.A. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 533 (2006) 101-109
15. Remels A.H., Gosker H.R., Schrauwen P., Langen R.C., and Schols A.M. Peroxisome proliferator-activated receptors: a therapeutic target in COPD?. Eur Respir J 31 (2008) 502-508
16. Standiford T.J., Keshamouni V.G., and Reddy R.C. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2 (2005) 226-231
17. Trifilieff A., Bench A., Hanley M., Bayley D., Campbell E., and Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 139 (2003) 163-171
18. Ward J.E., Fernandes D.J., Taylor C.C., Bonacci J.V., Quan L., and Stewart A.G. The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm Pharmacol Ther 19 (2006) 39-46
19. Patel H.J., Belvisi M.G., Bishop-Bailey D., Yacoub M.H., and Mitchell J.A. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive disease therapy. J Immunol 170 (2003) 2663-2669
20. Clayton R.A., Dick C.A., Mackenzie A., Nagasawa M., Galbraith D., Hastings S.F., et al. The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res 5 (2004) 4
21. Graff G., Daniel A.G., Milton T.B., Joan M.S., and John M.Y. Improved myeloperoxidase assay for quantitation of neutrophil influx in a rat model of endotoxin-induced uveitis. J Pharmacol Toxicol Methods 39 (1998) 169-178
22. Okutan H., Savas C., and Delibas N. The antioxidant effect of melatonin in lung injury after aortic occlusion-reperfusion. Interact CardioVasc Thorac Surg 3 (2004) 519-522
23. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
24. O'Donnell R.A., Peebles C., Ward J.A., Daraker A., Angco G., Broberg P., et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59 (2004) 837-842
25. Spond J., Billah M.M., Chapman R.W., Egan R.W., Hey J.A., House A., et al. The role of neutrophils in LPS-induced changes in pulmonary function in conscious rats. Pulm Pharmacol Ther 17 (2004) 133-140
26. Toward T.J., and Broadley K.J. Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: effect of rolipram and dexamethasone. J Pharmacol Exp Ther 298 (2001) 298-306
27. Jiang H., Qu J., He L., Pan J., Chen X., Li L., et al. Airway hyperresponsiveness induced by repetitive intraperitoneal injection of lipopolysaccharide and the involvement of inflammation and nitric oxide in guinea pigs. Inflamm Res 55 (2006) 286-292
28. Lapperre T.S., Willems L.N., Timens W., Rabe K.F., Hiemstra P.S., Postma D.S., et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest 131 (2007) 53-59
29. Brass D.M., Hollingsworth J.W., McElvania-Tekippe E., Garantziotis S., Hossain I., and Schwartz D.A. CD14 is an essential mediator of LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 293 (2007) L77-L83
30. Spond J., Chapman R., Fine J., Jones H., Kreutner W., Kung T.T., et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 14 (2001) 157-164
31. Dentener M.A., Louis R., Cloots R.H., Henket M., and Wouters E.F. Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release. Thorax 61 (2006) 478-484
32. Ma N., Cui D., Li J., and Lu L. A study on tumor necrosis factor alpha, macrophage inflammatory protein-2 and myeloperoxidase in blood, broncho-alveolar fluid and lung tissues of rat chronic bronchitis model. Zhonghua Nei Ke Za Zhi 38 (1999) 523-526
33. Andelid K., Bake B., Rak S., Linden A., Rosengren A., and Ekberg-Jansson A. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med 101 (2007) 888-895
34. Foschino Barbaro M.P., Carpagnano G.E., Spanevello A., Cagnazzo M.G., and Barnes P.J. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 20 (2007) 753-763
35. Lagente V., Planquois J.M., Leclerc O., Schmidlin F., and Bertrand C.P. Oxidative stress is an important component of airway inflammation in mice exposed to cigarette smoke or lipopolysaccharide. Clin Exp Pharmacol Physiol 35 (2008) 601-605
36. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 13 (2006) 70-80